Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression (Q41874321)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 February 2011

Language	Label	Description	Also known as
English	Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression	scientific article published on 15 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression (English)

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

1 reference

based on heuristic

inferred from title

Pieter Sonneveld

3

object named as

Pieter Sonneveld

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Robert Z Orlowski

8

object named as

Robert Z Orlowski

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

author name string

Jatin Shah

1

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Joan Bladé

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Jean-Luc Harousseau

4

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Keith Lantz

5

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Anil Londhe

6

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Colin Lowery

7

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

language of work or name

0 references

publication date

15 February 2011

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

117

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

16

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

3758-3762

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

5 June 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

5 June 2018

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

5 June 2018

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

5 June 2018

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

5 June 2018

New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

5 June 2018

Review of 1027 patients with newly diagnosed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

5 June 2018

Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

18 August 2018

Early response to therapy and survival in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

18 August 2018

Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

18 August 2018

Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4149315

18 August 2018

Identifiers

10.1002/CNCR.25937

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41874321&oldid=1929302229"